Header Logo

Connection

Michael Ihnat to Drug Screening Assays, Antitumor

This is a "connection" page, showing publications Michael Ihnat has written about Drug Screening Assays, Antitumor.
  1. A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett. 2005 Jan 20; 217(2):171-80.
    View in: PubMed
    Score: 0.060
  2. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.
    View in: PubMed
    Score: 0.045
  3. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorg Med Chem. 2021 01 01; 29:115887.
    View in: PubMed
    Score: 0.045
  4. Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. Bioorg Med Chem Lett. 2018 10 01; 28(18):3085-3093.
    View in: PubMed
    Score: 0.038
  5. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem. 2017 01 15; 25(2):545-556.
    View in: PubMed
    Score: 0.034
  6. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model. BMC Cancer. 2015 Jul 17; 15:522.
    View in: PubMed
    Score: 0.031
  7. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
    View in: PubMed
    Score: 0.028
  8. Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
    View in: PubMed
    Score: 0.025
  9. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. J Med Chem. 2010 Feb 25; 53(4):1563-78.
    View in: PubMed
    Score: 0.021
  10. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2008 May 15; 16(10):5514-28.
    View in: PubMed
    Score: 0.019
  11. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem. 2005 Sep 15; 13(18):5475-91.
    View in: PubMed
    Score: 0.016
  12. Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers. Mol Pharmacol. 1999 May; 55(5):938-47.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.